Commentary · 2017
Case reportPublished 2021
Thyroid Dysfunction Induced By Immune Check-Point Inhibitors
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The immune system is the core defense against cancer development and progression. Failure of the immune system to recognize and eliminate malignant cells plays an immense role in the pathogenesis of cancer. The paramount achievement in immunotherapy particularly Immune Checkpoint Inhibitors (ICI) over the recent decade has brought about a major paradigm shifts i n cancer treatment. ICIs represented mainly by inhibitory monoclonal antibodies Anti-cytotoxic T-lymphocyte Antigen4 (CTLA-4) (ipilimumab), anti-programmed cell death protein 1 (PD-1- pembrolizumab/nivolumab/cemiplimab), Anti-PD-1 Ligand molecules (PD-L-1-atezolizumab/avelumab/durvalumab) reactivate the immune system against tumor c ells but can also trigger a myriad of autoimmune side effects, termed immune-related Adverse Events (irAEs). Immunotherapy related adverse events typically have a delayed onset and prolonged duration compared to adverse events from chemotherapy, and its effective management depends on early recognition and prompt intervention with immune suppression and/or immunomodulatory strategies. The present review aims to raise awareness about the thyroid side effects of immune checkpoint inhibitors to physicians who are taking care of cancer patients and to specialists-mainly oncologists and endocrinologists who are urged to cooperate for the management of thyroid immunotoxicity.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 15 Jul 2024
VISTA is the predominant 2nd generation of ICI (Immune Check-Point Inhibitor) in Ph (-) myeloproliferative Neoplasm
Conference abstract · 29 Jun 2017
Lack of full re-constitution of exhausted HCV-specific CD8+ T cells following IFN-free DAA therapy is partially reversed upon immune check-point inhibitions during chronic HCV
Commentary · 23 May 2022
Alectinib-Induced Thyroid Dysfunction in a Non-Small Cell Lung Cancer Patient
Conference abstract · 7 Sep 2017
HPMA Copolymer-Bound Doxorubicin as Endogenous Vaccine Substantially Increases Therapeutic Effect of Check-Point Blockade Monoclonals: Acute versus Chronic Model
More from this journal
The newest in Journal of Clinical and Molecular Endocrinology.
Review article · 19 Apr 2025
Diabetes Management: Insights of Current and Future Trends
Research article · 15 Apr 2025
Safety and Efficacy of Fixed-Dose Combination of Dapagliflozin-Sitagliptin in Type 2 Diabetes Patients Uncontrolled on Metformin: A Multicentric Phase III Study
Commentary · 28 Feb 2025
Genetic Variants of Hormone Receptors and Their Clinical Implications
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Molecular Endocrinology
- SubjectDiabetes & Endocrinology
- SubjectGenetics & Molecular Biology

